Nothing Special   »   [go: up one dir, main page]

HK1174921A1 - Processes for the manufacture of a pharmaceutically active agent - Google Patents

Processes for the manufacture of a pharmaceutically active agent

Info

Publication number
HK1174921A1
HK1174921A1 HK13102334.6A HK13102334A HK1174921A1 HK 1174921 A1 HK1174921 A1 HK 1174921A1 HK 13102334 A HK13102334 A HK 13102334A HK 1174921 A1 HK1174921 A1 HK 1174921A1
Authority
HK
Hong Kong
Prior art keywords
manufacture
processes
active agent
pharmaceutically active
pharmaceutically
Prior art date
Application number
HK13102334.6A
Other languages
English (en)
Chinese (zh)
Inventor
Frans Therkelsen
Michael Harold Rock
Svend Treppendahl
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HK1174921A1 publication Critical patent/HK1174921A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
HK13102334.6A 2009-12-23 2013-02-25 Processes for the manufacture of a pharmaceutically active agent HK1174921A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28953009P 2009-12-23 2009-12-23
PCT/DK2010/050348 WO2011076212A2 (fr) 2009-12-23 2010-12-20 Procédés de fabrication d'un principe pharmaceutiquement actif

Publications (1)

Publication Number Publication Date
HK1174921A1 true HK1174921A1 (en) 2013-06-21

Family

ID=43567689

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13102334.6A HK1174921A1 (en) 2009-12-23 2013-02-25 Processes for the manufacture of a pharmaceutically active agent
HK14109681.9A HK1196352A1 (en) 2009-12-23 2014-09-26 Processes for the manufacture of a pharmaceutically active agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14109681.9A HK1196352A1 (en) 2009-12-23 2014-09-26 Processes for the manufacture of a pharmaceutically active agent

Country Status (37)

Country Link
US (3) US8461353B2 (fr)
EP (1) EP2516394B1 (fr)
JP (2) JP5864435B2 (fr)
KR (2) KR101873182B1 (fr)
CN (2) CN103694161B (fr)
AR (1) AR079580A1 (fr)
AU (1) AU2010335659B2 (fr)
BR (1) BR112012015749A2 (fr)
CA (1) CA2785440C (fr)
CL (1) CL2012001725A1 (fr)
CR (1) CR20120316A (fr)
CY (1) CY1118032T1 (fr)
DK (1) DK2516394T3 (fr)
DO (1) DOP2012000170A (fr)
EA (1) EA021440B1 (fr)
ES (1) ES2575666T3 (fr)
GE (1) GEP20146078B (fr)
HK (2) HK1174921A1 (fr)
HR (1) HRP20160518T1 (fr)
HU (1) HUE028806T2 (fr)
IL (2) IL220329A (fr)
MA (1) MA33945B1 (fr)
ME (1) ME02401B (fr)
MX (1) MX2012007078A (fr)
MY (1) MY159251A (fr)
NZ (2) NZ625798A (fr)
PL (1) PL2516394T3 (fr)
PT (1) PT2516394E (fr)
RS (1) RS54820B1 (fr)
SG (1) SG181910A1 (fr)
SI (1) SI2516394T1 (fr)
SM (1) SMT201600166B (fr)
TN (1) TN2012000279A1 (fr)
TW (1) TW201139370A (fr)
UA (1) UA111584C2 (fr)
WO (1) WO2011076212A2 (fr)
ZA (1) ZA201305936B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
CN104130174A (zh) * 2014-07-30 2014-11-05 天津市斯芬克司药物研发有限公司 一种吲唑衍生物及其制备方法
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
TW201630881A (zh) 2014-12-12 2016-09-01 Ｈ 朗德貝克公司 用於生產艾達魯吡啶之方法
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
CN108271369A (zh) * 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
EP3440055B1 (fr) * 2016-04-08 2020-03-11 H. Lundbeck A/S Procédé de fabrication d'idalopirdine par hydrogénation d'une imine
EP3333154A1 (fr) * 2016-12-07 2018-06-13 Sandoz Ag Forme cristalline d'un antagoniste sélectif du récepteur 5-ht6
CN113165992B (zh) * 2018-12-27 2024-08-06 豪夫迈·罗氏有限公司 制备外-n-(3-氮杂双环[3.2.1]辛烷-8-基)氨基甲酸叔丁酯的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
GB846675A (en) 1958-04-18 1960-08-31 Lab Francais Chimiotherapie Process for the production of a tryptamine derivative
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
WO1995018090A1 (fr) 1993-12-28 1995-07-06 Rhone-Poulenc Chimie Procede d'hydrogenation catalytique de nitriles en amines en presence d'un catalyseur de type nickel de raney dope
CN1082389C (zh) 1993-12-28 2002-04-10 罗纳布朗克化学公司 用于将腈催化加氢为胺的催化剂及其制备方法和用途
US5869653A (en) 1997-10-30 1999-02-09 Air Products And Chemicals, Inc. Hydrogenation of nitriles to produce amines
WO1999022561A2 (fr) 1997-10-31 1999-05-14 Koninklijke Philips Electronics N.V. Procede et appareil de reproduction sonore de la parole codee selon le principe lpc, par ajout de bruit aux signaux constitutifs
US6156694A (en) 1998-11-05 2000-12-05 E. I. Dupont De Nemours & Company Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst
ES2566056T3 (es) * 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2006169113A (ja) * 2004-12-10 2006-06-29 Dainippon Sumitomo Pharma Co Ltd インドール類の合成方法および合成中間体
US20090203577A1 (en) 2005-12-15 2009-08-13 Exelixis, Inc. Azepinoindole Derivatives As Pharmaceutical Agents
EP2002834A1 (fr) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryle/hétarylamides en tant que modulateurs du récepteur EP2
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010036362A1 (fr) * 2008-09-26 2010-04-01 Wyeth Inhibiteurs des récepteurs nucléaires de 1,2,3,6-tétrahydroazépino[4,5-b]indole-5-carboxylate
CN101531624A (zh) 2009-04-08 2009-09-16 大连凯飞精细化工有限公司 6-氟吲哚-3-乙腈的合成方法
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent

Also Published As

Publication number Publication date
SI2516394T1 (sl) 2016-07-29
CY1118032T1 (el) 2017-05-17
CA2785440C (fr) 2018-05-01
CR20120316A (es) 2012-08-16
JP5864435B2 (ja) 2016-02-17
AU2010335659B2 (en) 2015-05-21
HK1196352A1 (en) 2014-12-12
TN2012000279A1 (en) 2013-12-12
US9382205B2 (en) 2016-07-05
NZ625798A (en) 2014-10-31
PL2516394T3 (pl) 2016-09-30
IL220329A (en) 2016-03-31
EA021440B1 (ru) 2015-06-30
IL231141A (en) 2016-03-31
US20130245281A1 (en) 2013-09-19
CN102656146A (zh) 2012-09-05
CA2785440A1 (fr) 2011-06-30
CN103694161A (zh) 2014-04-02
TW201139370A (en) 2011-11-16
KR20170125417A (ko) 2017-11-14
DK2516394T3 (en) 2016-06-13
SG181910A1 (en) 2012-08-30
JP2016117734A (ja) 2016-06-30
EA201290552A1 (ru) 2012-12-28
WO2011076212A2 (fr) 2011-06-30
HUE028806T2 (en) 2017-01-30
US20150080584A1 (en) 2015-03-19
NZ600639A (en) 2014-07-25
IL231141A0 (en) 2014-03-31
US8901318B2 (en) 2014-12-02
SMT201600166B (it) 2016-07-01
CN103694161B (zh) 2015-09-09
ZA201305936B (en) 2015-09-30
KR101796330B1 (ko) 2017-11-09
WO2011076212A3 (fr) 2011-08-11
AU2010335659A1 (en) 2012-07-05
US8461353B2 (en) 2013-06-11
HRP20160518T1 (hr) 2016-06-03
MX2012007078A (es) 2012-07-20
MY159251A (en) 2016-12-30
IL220329A0 (en) 2012-08-30
JP6195605B2 (ja) 2017-09-13
EP2516394B1 (fr) 2016-03-16
CL2012001725A1 (es) 2012-11-30
JP2013515683A (ja) 2013-05-09
UA111584C2 (uk) 2016-05-25
ME02401B (fr) 2016-09-20
EP2516394A2 (fr) 2012-10-31
KR101873182B1 (ko) 2018-06-29
DOP2012000170A (es) 2012-08-31
MA33945B1 (fr) 2013-01-02
ES2575666T3 (es) 2016-06-30
KR20120112480A (ko) 2012-10-11
PT2516394E (pt) 2016-06-07
RS54820B1 (sr) 2016-10-31
GEP20146078B (en) 2014-04-10
US20110152539A1 (en) 2011-06-23
BR112012015749A2 (pt) 2015-09-15
CN102656146B (zh) 2014-12-17
AR079580A1 (es) 2012-02-01

Similar Documents

Publication Publication Date Title
HK1196352A1 (en) Processes for the manufacture of a pharmaceutically active agent
IL238337A0 (en) A process for the preparation of pharmaceutical active compounds
ZA201306237B (en) Solid forms of a pharmaceutically active substance
IL216906A0 (en) Active body
IL216904A0 (en) Active body
HU1000565D0 (en) Process for the preparation of pharmaceutically active compound and intermediers
HK1170277A1 (en) Medicinal agent case
PT2391352T (pt) Formas farmacêuticas para a libertação de compostos ativos
HK1167692A1 (en) Process for the preparation of a iodinating agent
GB201001203D0 (en) Use of pharmaceutically active compounds
HUP0900795D0 (en) Process for producing of pharmaceutically active agent
PL2616464T3 (pl) Udoskonalony sposób wytwarzania prekursora zasady sufentanilu
EP2389360A4 (fr) Procédé pour la préparation de zofénopril et ses sels pharmaceutiquement acceptables
EP2276476A4 (fr) Procédé de fabrication d une tige thermique destinée à l administration active d un médicament et tige thermique
GB0808827D0 (en) Novel pharmaceutically active compounds
GB0905557D0 (en) Pharmaceutical agent
GB0910754D0 (en) Pharmaceutical agent
GB0905558D0 (en) Pharmaceutical agent
GB0905555D0 (en) Pharmaceutical agent
GB0913956D0 (en) Pharmaceutical agent

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201218